Los Angeles, CA, United States of America

Reiko King

This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reiko King. Retrieved from https://idiyas.com/inventor/reiko-king

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Reiko King and Antibody-Interferon Fusion Proteins for Cancer Therapy

Introduction

Reiko King is an inventor associated with the University of California in Los Angeles, California. His patent work concerns approaches for strengthening adoptive T cell therapies, which use immune cells prepared outside the body and returned to a patient to target cancer.

Latest Patents

King is associated with 1 patent, titled “Antibody-Interferon Fusion Proteins for Enhancing Adoptive T Cell Therapies for the Treatment of Cancer.” The invention describes using antibody-interferon fusion proteins to enhance the cancer-fighting activity of adoptive T cell therapies. The approaches may apply to CAR T cells, tumor-infiltrating lymphocytes, virus-specific T cells, and T cell receptor transgenic T cells. These therapies aim to direct infused T cells to tumors, where they can attack cancer.

Career Highlights

The available information identifies King’s patent activity in cancer immunotherapy and his association with the University of California. His listed invention focuses on combining antibody-interferon fusion proteins with adoptive T cell treatments.

Collaborations

The listed collaborators include Alex Vasuthasawat and Sherie L. Morrison.

Conclusion

Reiko King’s patent describes a strategy for supporting adoptive T cell therapies with antibody-interferon fusion proteins, with the goal of improving immune-cell attacks against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…